Antithrombotic therapy in cardiac embolism.

Area of Science:

• Neurology
• Cardiology
• Pharmacology

Background:

• Anticoagulation is crucial for preventing secondary ischemic strokes in cardioembolic cases.
• It's also vital for primary stroke prevention in cardiac conditions, especially with vascular risk factors.
• Early initiation of anticoagulation is considered safe, even in moderate acute strokes.

Purpose of the Study:

• To assess the efficacy of early anticoagulation after cardioembolic stroke on patient outcomes.
• To explore the potential benefits of unfractionated heparin beyond anticoagulation, such as anti-inflammatory effects.

Main Methods:

• Review of existing clinical studies and animal models.
• Analysis of outcomes in patients receiving early anticoagulation post-cardioembolic stroke.
• Investigation into the mechanisms of action, including anti-inflammatory properties of unfractionated heparin.

Main Results:

• Evidence suggests early anticoagulation with unfractionated heparin may be associated with better patient outcomes.
• Anti-inflammatory properties of unfractionated heparin may contribute to improved stroke outcomes.
• The efficacy of early anticoagulation in relation to outcomes requires further adequate assessment.

Conclusions:

• Early anticoagulation is a recommended strategy for secondary prevention in cardioembolic ischemic stroke.
• Unfractionated heparin shows promise for improving stroke outcomes, potentially through anti-inflammatory pathways.
• Further research is needed to fully elucidate the benefits of early anticoagulation in stroke management.